Communiqué de presse : Rapport financier semestriel 2026 de Sanofi

Sanofi reported strong Q2 2026 results with 17.8% sales growth at constant exchange rates and business EPS of €2.09, leading to upgraded 2026 guidance. However, the company announced discontinuation of clinical development for amlitelimab in moderate-to-severe atopic dermatitis.

07/30/2026, 9:38 AM • GlobeNewswire

Press Release: Sanofi’s half-year financial report for 2026

Sanofi reported strong Q2 2026 results with 17.8% sales growth at constant exchange rates and business EPS of €2.09, leading to an upgrade of full-year 2026 guidance. However, the company announced discontinuation of clinical development for amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis.

07/30/2026, 9:38 AM • GlobeNewswire

The Smartest Dividend Stock to Buy With $1,000 Right Now (Spoiler: It Yields 5.6%.)

Sanofi, a French pharmaceutical company, is recommended as a promising dividend stock with a 5.6% yield that approaches 11% when including stock buybacks. The company is growing well with its flagship drug Dupixent showing 31% year-over-year sales growth, and the stock trades at an attractive valuation with a forward P/E ratio of 9, well below its five-year average.

07/28/2026, 10:30 PM • The Motley Fool

Communiqué de presse: Sanofi annonce sa décision de ne pas soumettre l’amlitélimab dans la dermatite atopique à des évaluations réglementaires mondiales

Sanofi has decided to halt clinical development of amlitélimab, a monoclonal antibody for moderate-to-severe atopic dermatitis, and will not submit it for regulatory approval worldwide. The company determined that efficacy and safety data do not support further development, as the drug would not represent a significant improvement over standard treatments. While the Phase 3 ESTUARY extension study showed long-term clinical response maintenance and acceptable safety profile, Sanofi maintains its 2026 financial guidance.

07/24/2026, 1:30 AM • GlobeNewswire

Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews

Sanofi has discontinued clinical development of amlitelimab, an OX40-ligand monoclonal antibody, for moderate-to-severe atopic dermatitis. The company determined that efficacy and safety evidence does not support further development, as the drug would not represent a meaningful improvement over current standard of care. The decision does not impact 2026 financial guidance. Amlitelimab development continues in celiac disease with results expected in H2 2026.

07/24/2026, 1:30 AM • GlobeNewswire

Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering

Scribe Therapeutics, a clinical-stage biotech company focused on in vivo CRISPR technologies, priced its IPO at $15 per share, raising $128.7 million from 8.58 million shares. The company will begin trading on Nasdaq under ticker SCTX on July 24, 2026. Additionally, Sanofi agreed to purchase 500,000 shares in a concurrent private placement at the same price.

07/23/2026, 9:08 PM • GlobeNewswire

Antiparasitic Drugs Market Report Released — Examines Antimalarials, Anthelmintics, Antiprotozoals, Ectoparasiticides, and Neglected Tropical Disease Therapies

The global antiparasitic drugs market is projected to grow from USD 23.30 billion in 2026 to USD 30.98 billion by 2032 at a 4.88% CAGR. Growth is driven by persistent parasitic disease burden, drug resistance, climate-sensitive vector transmission, and public health programs. Key opportunities include resistance-ready combination therapies, pediatric formulations, AI-enabled discovery, and diagnostics-linked prescribing, with Africa and Asia-Pacific leading endemic demand.

07/20/2026, 11:52 AM • GlobeNewswire

Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes

ResearchAndMarkets.com released a comprehensive report analyzing over 1,859 clinical-stage pharmaceutical and biotechnology partnership deals announced since 2020. The report provides detailed financial terms, deal structures, contract documents, and insights into negotiation dynamics for clinical-stage drug development collaborations, serving as a benchmarking resource for biopharma dealmakers.

07/17/2026, 6:48 AM • GlobeNewswire

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

07/15/2026, 11:00 AM • GlobeNewswire

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

Moderna and Recursion Pharmaceuticals represent two distinct approaches to biotech innovation: Moderna leverages proven mRNA technology with diversifying pipeline into oncology and rare diseases, while Recursion uses AI-driven drug discovery. Despite both operating at losses, Moderna is favored for 2026 due to its established revenue base and proven formula, whereas Recursion remains in earlier development stages with revenue expected to decline due to lower milestone payments.

07/03/2026, 11:14 AM • The Motley Fool

Dupilumab Achieves Record $11.9 Billion in Global Sales Amidst Continued Growth

Dupilumab (Dupixent) continues strong growth with €10.7 billion in 2023 sales and $4.34 billion in Q2 2025. FDA approval for COPD in September 2024 and expansion to chronic spontaneous urticaria in children unlock new market opportunities. The drug demonstrates clinical superiority over competitors like Xolair, with market projections extending to 2034 across multiple indications and geographic regions.

07/03/2026, 4:40 AM • GlobeNewswire

Communiqué de presse : Mise en ligne du document «Q2 2026 aide-mémoire »

Sanofi has published its Q2 2026 financial aide-mémoire to assist with quarterly financial modeling, with full Q2 2026 results scheduled for July 30, 2026. Additionally, Sanofi's Nexviazyme met all primary and secondary endpoints in a phase 3 study for infantile-onset Pompe disease, representing a significant clinical achievement for the company's pipeline.

07/01/2026, 1:30 AM • GlobeNewswire

Press Release: Availability of the aide-mémoire for Q2 2026 results

Sanofi announced the availability of its aide-mémoire for Q2 2026 results on July 1, 2026, to support financial modeling of quarterly results. The document covers non-comparable items, foreign currency impact, and share count. Full Q2 2026 results will be published on July 30, 2026.

07/01/2026, 1:30 AM • GlobeNewswire

Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows

Three high-yielding dividend stocks that recently hit 52-week lows are presented as potential bargain opportunities: Sanofi (5.7% yield) despite patent expiration concerns, AT&T (5.3% yield) facing Starlink competition worries, and Vici Properties (6.7% yield) offering stable dividend income. All three trade at attractive valuations with strong dividend coverage.

06/30/2026, 3:04 PM • The Motley Fool

Press Release: Sanofi Foundation opens new chapter centered on future generations

The Sanofi Foundation announced a strengthened commitment to children and young people facing serious diseases, climate, and humanitarian challenges. The foundation will allocate €15 million annually for programs benefiting children and youth, with partnerships including the Cerebral Palsy Foundation and AIDA. The foundation aims to impact over 6 million children and young people by 2030, while continuing humanitarian efforts that have reached 26 million patients across 45 countries.

06/25/2026, 2:00 AM • GlobeNewswire